Targets › INTEGRASE
8 programs from 6 companies in 52 trials: 15 Phase 3, 14 Phase 4, 12 Phase 2, 11 Phase 1; Infectious disease, Other, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: the race on INTEGRASE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Instituto Mexicano del Seguro Social | DTG/3TC Dolutegravir (integrase strand transfer inhibitor) and lamivudine (nucleoside reverse tran | INTEGRASE, TCEA1 | Phase 4 | HIV Infection | Dec 2026 |
| Harvard School of Public Health (HSPH) | DTG/ABC/3TC Integrase strand transfer inhibitor (dolutegravir) combined with nucleoside reverse transc | INTEGRASE, ABCC4, POLR2A | Phase 4 | HIV | Dec 2026 |
| José Antonio Mata Marín | DTG/3TC Integrase strand transfer inhibitor (INSTI) + nucleoside reverse transcriptase inhibitor ( | INTEGRASE, POLR2A | Phase 4 | HIV Infections | – |
| GSK | Cabotegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, INTEGRASE | Phase 3 | HIV Infections; Infection, Human Immunodeficiency Virus; Pre-exposure Prophylaxis; HIV-1 Infected Adults With Controlled Viremia … | Mar 2027 |
| GSK | Dolutegravir Human immunodeficiency virus type 1 integrase inhibitor | INSTI, RTASE, INTEGRASE, RT | Phase 3 | HIV; HIV Infections; HIV-1-infection; Acute HIV Infection … | Mar 2027 |
| Gilead Sciences | Bictegravir Human immunodeficiency virus type 1 integrase inhibitor | INTEGRASE, ABCC10 | Phase 3 | HIV-1-infection; HIV-1 Infection; HIV -1 Infection; HIV Infections | Jun 2027 |
| Gilead Sciences | Lepetegravir Integrase strand transfer inhibitor (INSTI) | INTEGRASE | Phase 2 | HIV-1-Infection | Jan 2028 |
| Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Raltegravir Human immunodeficiency virus type 1 integrase inhibitor | INTEGRASE | Phase 2 | HIV Infections | – |
HIV Infections (22) HIV-1-infection (11) HIV (5) HIV -1 Infection (2) Infection, Human Immunodeficiency Virus (1) Pre-exposure Prophylaxis (1) HIV-1 Infected Adults With Controlled Viremia (1) Pre-Exposure Prophylaxis (PrEP) (1) Hiv (1) HIV Infection (1) Acute HIV Infection (1) Healthy Volunteer (1)
small molecule (7), mixed (1)
GSK (2) Gilead Sciences (2) José Antonio Mata Marín (1) Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida (1) Instituto Mexicano del Seguro Social (1) Harvard School of Public Health (HSPH) (1)
INSTI (2) POLR2A (2) TCEA1 (1) RTASE (1) RT (1) ABCC10 (1) ABCC4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.